Ceva, a global animal health company, has recently announced a new partnership with Touchlight Genetics, a biotechnology firm specializing in DNA technology. This collaboration will allow Ceva to utilize Touchlight’s revolutionary dbDNA technology in its animal health products.
dbDNA, or doggybone DNA, is a synthetic DNA vector that boasts several advantages over traditional plasmid DNA. According to Touchlight, dbDNA is more stable, more efficient, and offers greater consistency in manufacturing. These qualities make it an attractive option for use in the development of vaccines and gene therapies.
Ceva hopes that incorporating Touchlight’s dbDNA technology into its animal health products will result in safer and more effective solutions for a variety of animal health concerns. The company is particularly excited about the potential applications of this technology in the development of vaccines for livestock and companion animals.
In a statement, Dr. Keith Foster, Global Head of Biology at Ceva, expressed his enthusiasm for the partnership, stating that Touchlight’s dbDNA technology could revolutionize the way vaccines are developed and produced for animal health.
This partnership between Ceva and Touchlight represents a significant step forward in the field of animal health technology. By harnessing the power of dbDNA, these two companies are poised to make major advancements in the development of new vaccines and therapies for animals around the world.
Overall, this collaboration has the potential to have a major impact on the animal health industry, offering new and innovative solutions to improve the health and well-being of animals. The integration of Touchlight’s dbDNA technology into Ceva’s products holds promise for the future of animal health research and development.
Source
Photo credit www.feedstuffs.com
